LearnGlossaryMarketStocksSuperinvestorsSign in

KLRA

Kailera Therapeutics, Inc.

Healthcare · $1.8B market cap

Verdict

We can't put a fair value on KLRA right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth—?
Sales growth—?
Free cash flow growth—?
Return on invested capital-24.5%✗

Follow KLRA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 7, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Nicholson Nur

Chief Technology Officer · 2026-09-07

Award

$3.6M

About Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works